Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: AEZS-108-050: Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer

 


AEZS-108-050: Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer


Trial Focus

Female Reproductive Cancer

Objective

         This is a clinical trial of AEZS-108 that will be administered by IV which is investigational or doxorubicin that will be administered by IV and is standard of care.

IRB Protocol #

13-2539

Trial Status

OPEN

Principle Investigator

SAKETH GUNTUPALLI

Sponsor

Aeterna Zentaris Inc.

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. If you are found to be eligible for this study, you will then enter the treatment period. Treatment will continue with the study drug for a maximum of 9 cycles. A cycle is a period of chemotherapy treatment followed by a period of rest. Treatment with doxorubicin will continue up to a pre-determined maximum dose, provided you tolerate the treatment and may benefit from the continuation of treatment. You will then visit the clinic at least every 3 weeks. // Eligibility criteria include but are not limited to 18 years or older with endometrial cancer.Eligibility criteria include but are not limited to 18 years or older with endometrial cancer.